Study of antiretroviral drug-resistant HIV-1 genotypes in northern Thailand: Role of mutagenically separated polymerase chain reaction as a tool for monitoring zidovudine-resistant HIV-1 in resource-limited settings

Journal of Acquired Immune Deficiency Syndromes

Volumn 36, Issue 5, 2004, Pages 1051-1056

  Saeng Aroon, Siriphan ^a   Wichukchinda, Nuanjun ^a   Myint, Lay ^b   Pathipvanich, Panita ^c   Ariyoshi, Koya ^a,b   Rojanawiwat, Archawin ^a   Matsuda, Masakazu ^b   Sawanpanyalert, Pathom ^a   Sugiura, Wataru ^b   Auwanit, Wattana ^a  

^a MINISTRY OF PUBLIC HEALTH   (Thailand)

^b NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^c LAMPANG HOSPITAL   (Thailand)

Author keywords

Antiretroviral drug; CRF01_AE; Drug resistance; HIV; Thailand

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; ZALCITABINE; ZIDOVUDINE;

ARTICLE; GENE MUTATION; GENE SEQUENCE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; THAILAND; VIRUS RESISTANCE;

DRUG RESISTANCE, VIRAL; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MUTATION; POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE INHIBITORS; THAILAND; TIME FACTORS; ZIDOVUDINE;

EID: 3342911910     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200408150-00008     Document Type: Article

References (25)

1. Hirsch MS, Brun-Vezinet F, Clotet B, et al. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an international AIDS society-USA panel. Clin Infect Dis. 2003;37:113-128.
2. Robertson DL, Anderson JP, Bradac JA, et al. HIV-1 nomenclature proposal, 1999. Available at: http://hiv-web.lanl.gov/conent/hiv-db/REVIEWS/review.html. Accessed on October 31, 2000.
3. Grossman Z, Vardinon N, Chemtob D, et al. Genotypic variation of HIV-1 reverse transcriptase and protease: comparative analysis of clade C and clade B. AIDS. 2001;15:1453-1460.
4. Ariyoshi K, Matsuda M, Miura H, et al. Patterns of point mutations associated with anti-retroviral drug resistance in CRF01_AE (subtype E) infection differ from subtype B infection. J Acquir Immune Defic Syndr. 2003;33:336-342.
5. Brenner B, Turner D, Oliveira M, et al. AV106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors. AIDS. 2003;17:F1-F5.
6. The Thai Working Group on HIV/AIDS Projection. Projections for HIV/AIDS in Thailand: 2000-2020. 2001. Karnsana Printing Press, Bangkok.
7. Pathipvanich P, Ariyosh K, Rojanawiwat A, et al. Survival benefit from non-highly active antiretroviral therapy in a resource-constrained setting. J Acquir Immune Defic Syndr. 2003;32:157-160.
8. Kanshana S, Simond RJ. National program for preventing mother-child HIV transmission in Thailand: successful implementation and lessons learned. AIDS. 2002;16:953-959.
9. Hecht FM, Grant RM, Petropoulos CJ, et al. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors. N Engl J Med. 1998;339:307-311.
10. Yerly S, Kaiser L, Race E, et al. Transmission of antiretroviral-drug- resistant HIV-1 variants. Lancet. 1999;354:729-733.
11. Salomon H, Wainberg MA, Brenner B, et al. Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use. Investigators of the Quebec Primary Infection Study. AIDS. 2000;14:F17-F23.
12. Frenkel LM, Wagner LE 2nd, Demeter LM, et al. Effects of zidovudine use during pregnancy on resistance and vertical transmission of human immunodeficiency virus type 1. Clin Infect Dis. 1995;20:1321-1326.
13. Richman DD, Guatelli JC, Grimes J, et al. Detection of mutations associated with zidovudine resistance in human immunodeficiency virus by use of the polymerase chain reaction. J Infect Dis. 1991;164:1075-1081.
14. Eastman PS, Urdea M, Besemer D, et al. Comparison of selective polymerase chain reaction primers and differential probe hybridization of polymerase chain reaction products for detemination of relative amounts of codon 215 mutant and wild-type HIV-1 populations. J Acquir Immune Defic Syndr. 1995;9:264-273.
15. Rust S, Funke H, Assmann G. Mutagenically separated PCR (MS-PCR): a high specific one step procedure for easy mutation detection. Nucleic Acids Res. 1993;21:3623-3629.
16. Frater AJ, Chaput CC, Beddows S, et al. Simple detection of point mutations associated with HIV-1 drug resistance. J Virol Methods. 2001;93:145-156.
17. Myint L, Ariyoshi K, Yan H, et al. Mutagenically separated PCR assay for rapid detection of M41L and K70R zidovudine resistance mutations in CRF01_AE (subtype E) human immunodeficiency virus type 1. Antimicrob Agents Chemother. 2002;46:3861-3868.
18. Birch C, Middleton T, Hales G, et al. Limited evolution of HIV antiretroviral drug resistance-associated mutations during the performance of drug resistance testing. J Acquir Immune Defic Syndr. 2003;32:57-61.
19. Decamps D, Flandre P, Joly V, et al. Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine or stavudine, each in combination with lamivudine and indinavir. J Acquir Immune Defic Syndr. 2002;31:464-471.
20. Larder BA, Kemp SD. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science. 1989;246:1155-1158.
21. Kellam P, Boucher CA, Larder BA. Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. Proc Natl Acad Sci USA. 1992;89:1934-1938.
22. Kellam P, Boucher CAB, Tijanagel JMGH, et al. Zidovudine treatment results in the selection of human immunodeficiency virus type 1 variants whose genotypes confer increasing levels of drug resistance. J Gen Virol. 1994;75:341-351.
23. UK Collaborative Group on Monitoring the Transmission of HIV Drug Resistance. Analysis of prevalence of HIV-1 drug resistance in primary infections in the United Kingdom. BMJ. 2001;322:1087-1088.
24. Hance AJ, Lemiale V, Izopet J, et al. Changes in human immunodeficiency virus type 1 populations after treatment interruption in patients failing antiretroviral therapy. J Virol. 2001;75:6410-6417.
25. Chan K, Galli R, Montaner J, et al. Prolonged retention of drug resistance mutations and rapid disease progression in the absence of therapy after primary HIV infection. AIDS. 2003;17:1256-1258.